Sažetak
Apstrakt
Uvod/Cilj. Brojna dosadašnja saznanja ukazala su na postojanje uloge osteokalcina, tradicionalnog parametra metaboličke aktivnosti kosti, u regulaciji metabolizma ugljenih hidrata. Cilj ove studije bio je da se utvrdi postojanje relacije između osteokalcina i izračunatih parametara procene stepena insulinske osetljivosti/rezistencije i sekretorne sposobnosti pankreasa kod gojaznih, nedijabetičnih ispitanika. Metode. Studijom je obuhvaćeno 57 gojaznih osoba (11 muškaraca i 46 žena) (indeks telesne mase – ITM: 41,03 ± 6,61 kg/m²) i 48 zdravih, normalno uhranjenih ljudi (ITM : 23,15 ± 2,04 kg/m²) koji odgovaraju ispitivanoj grupi, po starosti i polu. Svim ispitanicima izmerena je glukoza i insulin u toku dvočasovnog testa oralnog opterećenja glukozom (OGTT), osteokalcin i izračunate vrednosti Homeostatic Model Assessment (HOMA) indeksa (HOMA-IR, HOMA-B%), EISI (indeksa insulinske osetljivosti), (estimated first phase) i EFP (estimated second phase) druge faze (ESP) i procena sekretarnog kapaciteta pankreasnih ćelija druge faze (ESP). Koncentracija osteokalcina merena je u serumu, elektrohemiluminescentnom (ECLIA) metodologijom. Rezultati. Utvrđene su statistički značajno niže vrednosti osteokalcina u grupi gojaznih (ITM = 24,72 ± 9,80 vs 33,31 ± 10,89 ng/mL; p < 0,01). Linearnom korelacionom analizom dobijen je visok stepen pozitivne povezanosti osteokalcina sa EISI (r = 0,340; p < 0,01). Inverzna korelacija utvrđena je između osteokalcina i HOMA-IR (r = -0,276; p < 0,01), HOMA-B% (r = -0,337; p < 0,01), EFP (r = -0,332; p < 0,01) i ESP (r = -0,266; p < 0,01). ITM i osteokalcin imaju značajnu inverznu predikciju sa EISI i HOMA-IR, ali je nivo predikcije ITM bitno viši u odnosu na osteokalcin. Zaključak. Uticaj osteokalcina na sistem glikoregulacije je evidentan, ali je njegov udeo u tome bitno manji u odnosu na gojaznost i druge činioce povezane sa gojaznošću. Zbog toga se pri proceni mesta i uloge osteokalcina u glikoregulaciji, uvek mora imati u vidu da je osteokalcin, kao sistemski medijator, samo jedan od brojnih drugih faktora, pri čemu neki od njih, ispoljavaju dominantnije uticaje od osteokalcina.
Ključne reči
Array
Array
Array
Array
Array
Reference
REFERENCES
Lebovitz HE. Insulin resistance: Definition and consequences. Exp Clin Endocrinol Diabetes 2001; 109 Suppl 2: S135‒48.
Ionescu-Tirgoviste C, Ioacara S, Guja C, Sabau S, Lichiardopol R, Mi¬hai A, et al. A pathophysiological approach to metabolic syn¬drome using factor analysis in an adult Romanian popula-tion. Arch Physiol Biochem 2006; 112(3): 182‒8.
Fukumoto AS, Martin J. Bone as an endocrine organ. Trend En-docrinol Metab 2009; 20(5): 230‒6.
Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trend Endocrinol Metab 2008; 19(5): 161‒6.
Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130(3): 456‒69.
Karsenty G. Convergence between bone and energy homeosta-ses: leptin regulation of bone mass. Cell Metab 2006; 4(5): 341‒8.
Cvijovic G, Micić G, Kendereški A, Zoric S, Polovina S, Šumarac DM, et al. Glucose and bone metabolism – potential interac-tions. Acta Clin 2014; 14(3): 68‒72. (Serbian)
Motyl KJ, McCabe LR, Schwartz AV. Bone and glucose metabo-lism: A two-way street. Arch Biochem Biophys 2010; 503(1): 2‒10.
Wiecek A, Adamczak M, Chudek J. Adiponectin: an adipokine with unique metabolic properties. Nephrol Dial Transplant 2007; 22(4): 981‒8.
Aoki A, Muneyuki T, Yoshida M, Munakata H, Ishikawa SE, Suga¬wara H, et al. Circulating osteocalcin is increased in early-stage diabetes. Diabetes Res Clin Pract 2011; 92(2): 181‒6.
Caballero B. The global epidemic of obesity: an overview. Epi-de¬miol Rev 2007; 29: 1‒5.
Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van HT, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000; 23(3): 295‒301.
HOMA calculator software. Available from: https://www.dtu.ox.ac.uk/homacalculator/
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28(7): 412‒9.
Hardy OT, Czech MP, Corvera S. What causes the insulin resis-tance underlying obesity. Curr Opin Endocrinol Diabetes Ob-es 2012; 19(2): 81‒7.
Cifuentes M, Johnson MA, Lewis RD, Heymsfield SB, Chowdhury HA, Modlesky CM, et al. Bone turnover and body weight rela-tionships differ in normal weight compared to with havier postmenopausal women. Osteporosis Int 2003; 14: 116‒22.
Lucey AJ, Pashos GK, Thorsdottir I, Martinez JA, Cashman KD, Kiely M. Young overweight and obese women with lower cir-culating osteocalcin concentrations exibit higher insulin resis-tance and concentrations of c-reactive protein. Nutr Res 2013; 33(1): 67‒75.
Matthaei S, Stumvoll M, Kellerer M, Häring HU. Pathophysi-ology and pharmacological treatment of insulin resistance. Endocr Rev 2000; 21(6): 585‒618.
Sarkar PD, Choudhury AB. Relationships between serum osteo-calcin levels versus blood glucose, insulin resistance and mark-ers of systemic inflammation in central Indian type 2 diabetic patients. Eur Rev Med Pharmacol Sci 2013; 17(12): 1631‒5.
Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insu¬lin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sec-tional study in Malmö, Sweden. Diabet Med 2000; 17(4): 299‒307.
Saleem U, Mosley TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30(7): 1474‒8.
Yamamuchi T, Kamon J, Ito Y, Tsuchida A, Yokomiyo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423(6941): 762‒9.
Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differen-tially regulates bet cell and adipocyte gene expression and af-fects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 2008; 105(13): 5266‒70.
Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 2011; 48(4): 720‒5.
Kanazawa I. Osteocalcin as a hormone regulating glucose me-tabolism. World J Diabet 2015; 6(18): 1345‒54.